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Abstract
Background: Intronic and intergenic long noncoding RNAs (lncRNAs) are emerging gene expression regulators.
The molecular pathogenesis of renal cell carcinoma (RCC) is still poorly understood, and in particular, limited studies
are available for intronic lncRNAs expressed in RCC.
Methods: Microarray experiments were performed with custom-designed arrays enriched with probes for lncRNAs
mapping to intronic genomic regions. Samples from 18 primary RCC tumors and 11 nontumor adjacent matched
tissues were analyzed. Meta-analyses were performed with microarray expression data from three additional human
tissues (normal liver, prostate tumor and kidney nontumor samples), and with large-scale public data for epigenetic
regulatory marks and for evolutionarily conserved sequences.
Results: A signature of 29 intronic lncRNAs differentially expressed between RCC and nontumor samples was
obtained (false discovery rate (FDR) <5%). A signature of 26 intronic lncRNAs significantly correlated with the RCC
five-year patient survival outcome was identified (FDR <5%, p-value ≤0.01). We identified 4303 intronic antisense
lncRNAs expressed in RCC, of which 22% were significantly (p <0.05) cis correlated with the expression of the mRNA
in the same locus across RCC and three other human tissues. Gene Ontology (GO) analysis of those loci pointed to
‘regulation of biological processes’ as the main enriched category. A module map analysis of the protein-coding
genes significantly (p <0.05) trans correlated with the 20% most abundant lncRNAs, identified 51 enriched GO terms
(p <0.05). We determined that 60% of the expressed lncRNAs are evolutionarily conserved. At the genomic loci
containing the intronic RCC-expressed lncRNAs, a strong association (p <0.001) was found between their transcription
start sites and genomic marks such as CpG islands, RNA Pol II binding and histones methylation and acetylation.
Conclusion: Intronic antisense lncRNAs are widely expressed in RCC tumors. Some of them are significantly altered in
RCC in comparison with nontumor samples. The majority of these lncRNAs is evolutionarily conserved and possibly
modulated by epigenetic modifications. Our data suggest that these RCC lncRNAs may contribute to the complex
network of regulatory RNAs playing a role in renal cell malignant transformation.
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Background
Renal cell carcinoma (RCC) is the most common cancer
in adult kidney corresponding to nearly 3% of all adult
malignancies worldwide [1], being an important cause of
cancer morbidity and mortality [1]. Clear cell renal cell
carcinoma (ccRCC) subtype is the most prevalent [2],
making it especially important to identify the molecular
changes associated with malignant transformation and
with longer survival [3,4]. The malignant transformation
has been associated to several changes in gene expres-
sion patterns, which are critical to several steps of tumor
progression [5].
The noncoding RNAs (ncRNAs) exceed the number of
protein-coding genes several fold [6], and both micro-
RNAs (21–24 nt) (miRNAs) and long ncRNAs (≥ 200 nt)
(lncRNAs) are now emerging as mammalian transcription
key regulators in response to developmental or environ-
mental signals [7-9]. The lncRNAs are classified based on
intersection with protein-coding genes; when they map
outside a protein-coding locus they are denominated long
intergenic ncRNAs (lincRNAs) [9]. Otherwise they are
classified as intronic, and in this case they can be either
sense or antisense with respect to the direction of tran-
scription of the host protein-coding gene in the locus [9].
Following the first reports of miRNA expression pro-
files associated with different types of cancer [10,11],
several independent studies over the past five years iden-
tified a number of miRNAs differentially expressed in
RCC that are correlated with malignancy [12-18] and
with RCC subtypes classification [19,20]. In addition, a
metastasis signature comprehending four miRNAs was
recently described for ccRCC [21].
It has become evident that not only miRNAs but also
lncRNAs are important players in cancer [22-27]. Stud-
ies on lncRNA expression have mainly been focused on
the lincRNAs [28,29], essentially to simplify their ana-
lysis by avoiding possible complications arising from
overlapping protein-coding genes [30]. Thus, recent
transcriptome sequencing showed that lincRNAs are ab-
errantly expressed in a variety of human cancers [31]. A
transcriptome sequencing study over a prostate cancer
cohort identified the lincRNA PCAT1 as implicated in
malignancy progression [32]. In human lung adenocar-
cinoma, another lincRNA, MALAT1, has been associated
with tumor metastasis [33] and is overexpressed in five
other types of human cancers [34]. In a rare subtype of
RCC, namely t(6;11) RCC, it has been described that
MALAT1 is fused to TFEB gene [35,36]. Recently, it has
been shown that Xist lincRNA is a potent suppressor of
hematologic cancer in mice [37].
Intronic lncRNAs constitute the major components of
the mammalian ncRNA transcriptome [38], and the in-
tronic lncRNAs are possibly related to a fine-tuning
regulation of gene expression patterns across the entire
genome [39]. Although thousands of putative intronic
lncRNAs have been identified [9,38,40,41], it is yet to be
determined which ones are functional. Also, it is a chal-
lenge to determine which ones are either independently
transcribed or are by-products of pre-mRNA processing,
with the levels of some of their intronic portions being
independently regulated [38,42]. In fact, the mechanism
of action of only a few intronic lncRNAs has been char-
acterized in the context of cancer [42-44]. In addition,
there is a number of studies reporting the correlation of
expression patterns of intronic lncRNAs with cancer,
such as intronic lncRNAs correlated to the degree of
tumor differentiation in prostate cancer [45], intronic
lncRNAs differentially expressed in primary and meta-
static pancreatic cancer [46] and in dasatinib-treated
chronic myeloid leukemia patients with resistance to
imatinib [47]. In breast and ovarian cancer, Perez et al.
[48] identified 15 aberrantly expressed ncRNAs, of
which at least three are intronic [48]. In renal carcin-
oma, there are sparse studies regarding long noncoding
RNAs. Our group previously identified seven intronic
lncRNAs significantly deregulated in a set of six ccRCC
tumor samples when compared with adjacent nontumor
tissues [49]. Using a microarray approach, another study
revealed tumor-associated lincRNAs when comparing
gene expression profiles in six pairs of ccRCC and adja-
cent nontumor tissues [50].
In the present work, our study focused on the analysis
of unspliced intronic lncRNAs, the class of lncRNAs that
is the least studied one, in an attempt to point to pos-
sible new key molecules and pathways involved in renal
carcinogenesis. In order to analyze gene expression pat-
terns in tissue samples from RCC patients, we used
herein two different microarray platforms enriched with
probes for these intronic lncRNAs. We identified intronic
lncRNAs whose differential expression was significantly
correlated with RCC malignancy or with patient survival
outcome. We also identified sets of intronic lncRNAs that
are co-regulated in cis or in trans with protein-coding
mRNAs encoding genes associated with transcriptional
regulation and with kidney functions. Finally, our data
demonstrate that RCC-expressed lncRNA loci are signifi-
cantly associated with CpG islands and histone regulatory
modifications typical of active RNA Pol II-transcribed
genes, and that the intronic lncRNAs expression pattern
in RCC is markedly tissue-specific and evolutionarily
conserved.
Results
Expression signature of intronic long noncoding RNAs
associated to malignancy in clear cell renal cell carcinoma
Based on our previous work with kidney tumor samples
that identified a gene expression signature of 64 genes
associated to ccRCC that included only 7 intronic
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lncRNAs [49], we looked for additional intronic lncRNAs
differentially expressed between ccRCC and nontumor tis-
sues. For this purpose, we analyzed eleven pairs of tumor
(T) and matched adjacent nontumor renal tissue (N) sam-
ples from ccRCC patients. Clinical and pathological data
of each patient are shown in Additional file 1: Table S1.
Gene expression was measured with a non-strand-
specific 4 k-element cDNA microarray platform that in-
terrogates the expression of 722 intronic lncRNAs, 262
lincRNAs and 2371 protein-coding genes [45,49], now
employing an improved T7 RNA-polymerase-based
cRNA linear amplification and labeling protocol, as de-
scribed under Methods.
A ccRCC-associated gene expression profile comprised
of 29 intronic lncRNAs was identified with statistically
significant differential expression, by comparing the ex-
pression of tumor and paired nontumor samples from
eleven patients (FDR ≤5%, 1.5-fold change) (Figure 1).
To minimize the contribution of each individual patient
sample to the set of significantly altered genes [51] the
statistical analysis has included a leave-one-out cross-
validation procedure; essentially, one sample was removed
at a time, and every time a new set of significantly altered
genes was determined using the remaining ten samples,
ultimately pointing to the most consistently altered gene
set, which is common to all leave-one-out sets (see Material
and methods for details). In addition, 9 non-annotated
lincRNAs and 2 RefSeq lincRNAs were identified as sig-
nificantly differentially expressed, totalizing 40 altered
lncRNAs. Among the 40 lncRNAs, 26 were downregulated
and 14 were upregulated in tumors when compared with
nontumor tissues (Figure 1). The list of lncRNAs with
altered expression is shown in Table 1.
Protein-coding genes differentially expressed in ccRCC
and meta-analysis of malignancy related genes
To evaluate our microarray performance, we searched for
protein-coding genes differentially expressed in our renal
cancer samples and compared this set of genes with lists
of protein-coding genes differentially expressed in ccRCC
from nine published studies [5,49,52-58]. We identified a
set of 217 protein-coding genes differentially expressed in
our ccRCC samples relative to nontumor adjacent renal
tissue (FDR <5%, leave-one-out cross-validation, 1.5-fold
change) (Additional file 2: Figure S1; Additional file 3:
Table S2). The meta-analysis is summarized in Table 2
and is described in detail in Additional file 3: Table S2. A
total of 170 (78%) protein-coding genes are expressed in
common between our study and the other nine previous
studies. Most genes expressed in common (142/170; 83%)
showed a concordant expression pattern.
Additionally, we looked at the expression of the 11
host protein-coding genes (among the 29) for which
there were probes for the mRNA from the loci related to
the intronic lncRNAs candidates. Of these, 10 protein-
coding genes were detected as expressed in RCC (IGFBP7,
RAB31, PAPPA, ARPC1B, PTEN, HDAC5, NR2C2,
MAP2K1, PTPN3, DNAJC3). Only two were detected as
significantly differentially expressed in RCC compared
with nontumor, namely RAB31 (fold-change =2.2) and
ARPC1B (fold-change =1.84) (Additional file 3: Table S2).
The fold-change and the direction of change of the
protein-coding genes in tumors are in agreement with the
literature data from the meta-analyses shown below.
Because of the limited representation of protein-coding
genes in the 4 k array, we performed a meta-analysis with
the ccRCC microarray studies in the literature [5,49,52-58],
looking for protein-coding genes differentially expressed
in the loci of the 29 intronic lncRNA candidates of our
study. Of the 29 protein-coding genes, 28 were detected
as expressed in at least one study included in our
meta-analysis (Table 1, last column). Among them, we
Figure 1 lncRNA expression signature of malignancy in clear
cell renal cell carcinoma (ccRCC). Heat map of 40 differentially
expressed lncRNAs (rows) identified in 11 ccRCC patients (columns).
Patient ID numbers are shown at the bottom. (false-discovery-rate
<5%; fold-change ≥1.5). There are 29 intronic lncRNAs (identified by
their host-gene symbols) and 11 lincRNAs. Blue indicates lower ex-
pression, and red, higher expression in tumor (T) tissues in relation
to adjacent nontumor (N) tissues.
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Table 1 List of 40 lncRNAs differentially expressed in RCC from the present work: 29 intronic lncRNAs and 11 lincRNAs
(FDR <5%; >1.5-fold change)
GenBank
accession
of probe§
lncRNA type RefSeq of
host gene
Host gene
symbol
Genomic coordinates FDR (%) Fold change
of lncRNA
Average fold
change of
host gene†
AW835362 Intronic NM_001553 IGFBP7 chr4:57928550-57929060 0.00 4.88 −1.15 (2/4)
AW881130 Intronic NM_006868 RAB31 chr18:9711672-9712160 0.00 3.72 2.56 (5/5)
BF881464 Intronic NM_004930 CAPZB chr1:19724054-19724494 0.00 2.03 1.34 (3/5)*
AW846722 Intronic NM_024113 C11orf49 chr11:47169567-47169799 0.00 2.02 −0.34 (2/4)
AW815357 Intronic NM_153326 AKR1A1 chr1:46029945-46030338 0.00 1.77 −2.20 (3/3)
AW937741 Intronic NM_003137 SRPK1 chr6:35819568-35820194 2.46 1.7 −1.37 (3/4)
BF350736 Intronic NM_025228 TRAF3IP3 chr1:209954933-209955401 1.93 1.65 1.39 (4/4)
CK327196 Intronic NM_002581 PAPPA chr9:119104917-119105402 1.86 1.63 −3.49 (5/5)
BF743551 Intronic NM_005720 ARPC1B chr7:98991157-98991537 1.37 1.6 2.90 (5/5)
AW748493 Intronic NM_001098634 RBM47 chr4:40563872-40564416 3.16 −1.52 −1.82 (4/4)
CK327206 Intronic NM_015995 KLF13 chr15:31628837-31629268 2.46 −1.53 1.19 (1/4)
CK327137 Intronic NM_173355 UPP2 chr2:158886308-158886559 1.37 −1.55 −6.05 (1/2)
BE168993 Intronic NM_005882 MAEA chr4:1318234-1318651 1.68 −1.56 −1.63 (2/4)
BE181783 Intronic NM_001893 CSNK1D chr17:80226176-80226555 0.75 −1.63 −1.28 (3/3)*
AW836810 Intronic NM_000314 PTEN chr10:89630175-89630699 0.00 −1.63 1.74 (4/4)
BG010306 Intronic NM_005474 HDAC5 chr17:42175003-42175469 0.75 −1.66 0.00 (0/3)
BF327015 Intronic NM_003298 NR2C2 chr3:15052840-15053222 0.00 −1.7 −0.34 (0/5)
BF882783 Intronic NM_004924 ACTN4 chr19:39203995-39204367 0.75 −1.74 −0.29 (1/5)
BF357721 Intronic NM_002755 MAP2K1 chr15:66764897-66765436 0.00 −1.78 1.52 (3/4)
BF360792 Intronic NM_020387 RAB25 chr1:156032114-156032418 0.75 −1.79 −5.17 (4/4)
CK327077 Intronic NM_001170704 MBNL3 chrX:131621693-131622042 0.00 −1.9 −0.79 (0/5)
CK327106 Intronic NM_005781 TNK2 chr3:195591793-195592189 0.00 −1.95 −1.16 (4/4)*
BF768459 Intronic NM_004924 ACTN4 chr19:39200205-39200785 0.00 −2.01 −0.29 (1/5)*
BF368747 Intronic NM_006516 SLC2A1 chr1:43409776-43410148 0.00 −2.01 4.43 (5/5)
BE080597 Intronic NM_002829 PTPN3 chr9:112237298-112237614 0.00 −2.13 −2.15 (5/5)
BF332192 Intronic NM_017890 VPS13B chr8:100419550-100419768 0.00 −2.13 1.37 (3/5)
BE168995 Intronic NM_018253 YY1AP1 chr1:155656314-155656660 0.00 −2.23 n.d.
CK327034 Intronic NM_015575 GIGYF2 chr2:233592945-233593379 0.00 −2.45 1.16 (2/4)
BF368584 Intronic NM_006260 DNAJC3 chr13:96432041-96432369 0.00 −2.81 1.74 (1/1)
BF368636 lincRNA1
RefSeq ncRNA
NR_028288 TCL6 chr14:96131134-96131552 0.00 1.92 -
AW880409 lincRNA2
RefSeq ncRNA
NR_003255 and
NR_001564
TSIX and XIST chrX:73042786-73043127 1.95 1.74 -
AW880864 lincRNA3 n.a. n.a. chr9:18430899-18431447 0.41 1.68 -
BF987841 lincRNA4 n.a. n.a. chr14:53107162-53107542 1.12 1.64 -
AW880828 lincRNA5 n.a. n.a. chr2:26955660-26956225 0.78 1.63 -
BF333219 lincRNA6 n.a. n.a. chr12:49324983-49325465 0.75 −1.63 -
BG009895 lincRNA7 n.a. n.a. chr21:19119867-19120311 0.00 −1.74 -
BE710971 lincRNA8 n.a. n.a. chr17:18176339-18176682 0.00 −1.93 -
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identified 13 genes with significantly altered expression in
tumor compared to nontumor, displaying fold-changes
greater than > |1.5|, of which 7 were altered in the same
direction of the intronic lncRNA (concordantly changed)
and 6 were altered in the opposite direction (inversely
changed) (Table 1, last column).
Intronic lncRNA expression profile is correlated to the
patient survival outcome in RCC
Next, we asked if there was a signature of intronic
lncRNAs associated to the patient survival outcome in
ccRCC. We considered the lncRNA expression data of
the paired and unpaired tumor samples from sixteen
ccRCC patients who had a cancer-specific death or were
disease-free within a 5-year follow-up after surgery
(Additional file 1: Table S1). A supervised statistical ana-
lysis identified a 26-gene intronic lncRNA expression
profile (Additional file 4: Figure S2; Additional file 5:
Table S3) that was significantly correlated to the patient
survival outcome (SAM statistical test, FDR ≤5%, com-
bined with Golub’s discrimination score, p <0.01; see
Material and methods for details). No lincRNAs in the
array were identified as correlated to survival. Most of
the altered intronic lncRNAs present in this signature
(24/26, i.e. 92%) were down regulated in the disease-free
group. Patient status (PS, Additional file 4: Figure S2B,
first line) refers to the disease outcome within the 5-year
follow-up after surgery, and it should be noted that it
was the sole criterion used for the supervised statistical
analysis of correlated lncRNA expression. For comparison,
an additional eight clinical and pathological parameters re-
lated to each patient are shown (Additional file 4: Figure S2).
Interestingly, a set of eight intronic lncRNAs was detected
in common, both in the patient survival profile and in the
ccRCC-associated gene expression profile described above
(Additional file 5: Table S3, last column). Validation of the
patient survival profile with an independent, larger patient
cohort is warranted.
Real-time qPCR validation assay
To further validate the microarray expression data, we
performed independent measurements of RNA abun-
dance in tumor samples using real-time quantitative
PCR. The limited amount of RNA available from patient
samples was a challenge, and we selected only eight in-
tronic lncRNA candidates to perform these assays. In
addition, due to the lack of available RNA from all pa-
tients, we could only test a fraction of the cohort. Four
lncRNAs mapping to intronic regions, namely ncC11orf49,
ncHDAC5, ncRAB31 and ncSRPK1, showed a significant
(p <0.05) differential expression between tumor and non-
tumor paired samples as measured by qPCR (Figure 2A-D);
transcripts from these four loci showed an expression
pattern comparable to the observed in the array, thus cor-
roborating the differential expression observed in the
microarray analysis (Pearson correlation r = 0.96). Real-
time qPCR measurements for transcripts from other four
intronic regions (ncACTN4, ncIGFBP7, ncMAP2K1,
ncPTEN) presented high expression variability and could
not be validated (data not shown).
Table 1 List of 40 lncRNAs differentially expressed in RCC from the present work: 29 intronic lncRNAs and 11 lincRNAs
(FDR <5%; >1.5-fold change) (Continued)
BE718437 lincRNA9 n.a. n.a. chr17:56595754-56596085 0.00 −1.94 -
BF333731 lincRNA10 n.a. n.a. chr17:62118605-62119046 0.00 −2.19 -
AW996872 lincRNA11 n.a. n.a. chr15:58887770-58888280 0.00 −2.45 -
§ Probes are double-stranded cDNA, with the sequences that are indicated in the EST accession numbers from GenBank.
† Host protein-coding genes expression from a meta-analysis of ccRCC gene expression studies [54-58] obtained with the Oncomine™ Software tool: average fold
change (FC) values in tumor relative to nontumor tissues of all studies are shown. The numbers in bold indicate FC values in the range −1.5 > FC > 1.5. The numbers in
parenthesis represent: number of studies with significant differential expression of that gene/number of studies that have detected the expression of that gene.
* For this protein-coding gene more than one probe was present in some of the studies, and these additional probes showed an opposite expression pattern in
the Oncomine Software. We show the most frequent pattern for this gene among all studies.
Table 2 Summary of meta-analysis of the 217 protein-coding genes ccRCC signature from the present work with nine
publicly available microarray studies comparing tumor and nontumor tissue samples from ccRCC patients
Takahashi
et al. [52]
Skubitz
et al. [5]
Higgins
et al. [56]*
Lenburg
et al. [54]*
Liou
et al. [53]
Jones
et al. [55]
Gumz
et al. [57]*
Beroukhim
et al. [58]
Brito
et al. [49]
# of genes in common 4 2 35 93 4 42 109 1 29
# of concordant genes§ 4 2 29 78 4 38 94 1 29
% of concordance 100.0 100.0 82.9 83.9 100.0 90.5 86.2 100.0 100.0
§ Genes differentially expressed in the same direction (up or down) of that from our study.
* Lists of differentially expressed genes (p <0.05) obtained from Oncomine™ database. The lists of differentially expressed genes from the other studies in this
Table were obtained directly from the published papers (see References).
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Transcriptional orientation assay
For the four intronic lncRNAs ncC11orf49, ncHDAC5,
ncRAB31 and ncSRPK1 with differential expression in
ccRCC validated by RT-qPCR assay, transcriptional
orientation (sense and/or antisense) was measured by
strand-specific reverse transcription followed by PCR
(Figure 2E) in the ccRCC and nontumor patient tissues.
Three loci showed evidence of both sense and antisense
messages (ncC11orf49, ncHDAC5 and ncSRPK1). For the
ncRAB31 locus, only a transcript with the same (sense)
orientation of the corresponding protein-coding mRNA
was detected (Figure 2E). The pattern of strand-oriented
expression detected in human kidney tissues (pool of
ccRCC or nontumor samples) was reproduced in kidney
human cell lines originated from tumor (786-O) and
nontumor (RC-124) (Figure 2E). To ensure that the
strand-oriented determinations were free from technical
artifacts, a control for the absence of self-annealing dur-
ing reverse transcription (RT) and for the absence of
genomic contamination was performed with the RT re-
action step without any primer, followed by PCR with
the pair of primers for the respective lncRNA; no prod-
ucts were detected in the controls (Figure 2E, control
lanes).
ncHDAC5: characterization of the intronic lncRNA
decreased in RCC
The intronic lncRNA ncHDAC5, which is expressed
from the locus of the regulatory histone-modifying en-
zyme HDAC5, was chosen for a more detailed char-
acterization, because we identified it as decreased in the
malignancy profile and increased in the patients with a
poor survival outcome. We extended the ncHDAC5 tran-
script by 3′- and 5′-RACE-PCR with a fetal kidney RACE
library, sequenced the products and determined the
ncHDAC5 RNA expressed in kidney to have 1695 nt
(GenBank Accession JX899681). Stability of the ncHDAC5
transcript was examined by the actinomycin-treatment
assay, revealing a half-life of 42 min in the 786-O kidney
tumor cell line (Additional file 6: Table S4A).
The abundances of the ncHDAC5 lncRNA and of the
HDAC5 protein-coding mRNA were measured in paired
tumor and nontumor samples from ten ccRCC patients
and are shown in Figure 3A. It is apparent that for the
majority of patients (7/9) the expression level of the
ncHDAC5 was significantly lower (p <0.05) in tumor
than in nontumor tissues (fold change relative to nontu-
mor < 1) (Figure 3A, light blue). On the other hand, the
protein-coding gene expression in tumor did not show a
Figure 2 Relative quantification and transcriptional orientation of intronic lncRNAs differentially expressed in ccRCC. Expression of
(A) ncC11orf49, (B) ncHDAC5, (C) ncRAB31 and (D) ncSRPK1 was evaluated in tumor and adjacent nontumor paired samples from clear cell RCC
patients by qPCR. Tumor expression relative to paired nontumor in each patient sample is shown. lncRNA expression was normalized by HPRT1
gene expression. The statistical significance of the differential expression was evaluated by the t-test (p < 0.05). (E) For each gene, strand-specific
reverse transcription (RT) followed by PCR shows the presence of intronic messages transcribed from the antisense (AS) and/or the sense (S)
strands, in a pool of 10 ccRCC tissues, in a pool of 10 matched nontumors, or in the 786-O tumor and the RC-124 nontumor kidney cell lines. A
control (C) for the absence of RNA self-annealing during reverse transcription and for the absence of genomic contamination was performed with
an RT reaction step without primer (+ RT, - RT primer), followed by PCR with the pair of primers for the corresponding lncRNA.
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Figure 3 Characterization of the intronic lncRNA expressed from the HDAC5 locus. (A) Relative abundances of the ncHDAC5 lncRNA (light
blue) and of the HDAC5 protein-coding mRNA (dark blue) are shown as fold change in the tumor relative to the matched nontumor sample for
each of ten ccRCC patients. Patients are order according to the fold change of the ncHDAC5. (B-F) Regulatory and conserved elements from the
ENCODE database are shown at the genomic region of the HDAC5 protein-coding gene from intron 3 to intron 11. Arrowheads in (B) show the
opposing directions of transcription of the HDAC5 and the ncHDAC5 RNAs. In (C) the RNA Polymerase II binding sites measured in 14 cell lines,
and the CTCF transcriptional repressor insulator binding site are shown. In (D) the histone modification marks H3K27ac, H3K4me3, H3K4me1,
H3K36me3 and H3K27me3 are shown. In (E) the HMM histone state segmentation annotation is shown, comprising a predicted active promoter
(red), a strong enhancer (orange) and an insulator (blue) region. In (F) the vertebrate conservation and the CpG islands tracks are shown (no
marks detected in the latter). (G) The most stable conserved secondary structure predicted by the RNAz tool (P = 0.99) for a segment within
ncHDAC5. The segment spans 110 nt along the 1.7 kb-long lncRNA transcribed in the antisense direction in the HDAC5 locus.
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significant pattern of change relative to nontumor (p =0.18),
the fold-change varying widely from 0.3 to 2.3 (Figure 3A,
dark blue). In fact, these qPCR results confirm the 4 k-
array expression measurements of HDAC5 mRNA, which
showed no significant changes in tumor compared with
nontumor (see above). The expression of HDAC5 mRNA
was not correlated to the expression of ncHDAC5 RNA
(Pearson r =0.41, p =0.23), which indicates that the mRNA
and the lncRNA are independently transcribed and/or
independently regulated.
To further characterize the intronic ncHDAC5 lncRNA,
we looked at public genomic databases [59-61] for gen-
omic marks of expression regulation in the genomic locus
of HDAC5 from intron 3 to intron 11 (Figure 3B-F). We
identified RNA Pol II binding exclusively on intron 3, at
the vicinity of exon 4, in 14 different cell lines (Figure 3C).
Further downstream on intron 3, we found CTCF tran-
scriptional repressor insulator binding (Figure 3C); it is
known that insulators limit the activity of promoters and
enhancers to certain functional domains. In addition, we
identified the occurrence of the active enhancer-associated
histone mark acetylation of histone 3 lysine 27 (H3K27ac)
and of the promoter-associated histone mark trimethyla-
tion of histone 3 lysine 4 (H3K4me3) co-localized with the
RNA Pol II binding site (Figure 3D). The regulatory-
element-associated monomethylation of histone H3 lysine
4 (H3K4me1) as well as the active-transcription-associated
histone mark trimethylation of histone 3 lysine 36
(H3K36me3) were identified along the genomic region
encompassing the intronic ncHDAC5 (Figure 3D). The
repressive mark trimethylation of histone 3 lysine 27
(H3K27me3) was detected at low abundance in this locus,
at a frequency similar to that of the exonic regions of the
HDAC5 gene, as expected for actively transcribed regions
(Figure 3D). In fact, the HMM histone state segmentation
analysis (Figure 3E) predicts an active promoter (red) at
the left-hand part of the ncHDAC5 locus, a strong enhan-
cer region (orange) in the middle, and an insulator region
(blue) at the right-hand side. Taken together, these
ENCODE data suggest that the regulatory elements
present in the locus, along with RNA Pol II can drive the
transcription of ncHDAC5 in the antisense direction, hav-
ing the ncHDAC5 TSS in the vicinity of the RNA Pol II
binding site, as indicated in Figure 3B. It is likely that the
sense transcript detected by strand-specific RT-qPCR in
this intronic locus, reflects the presence of HDAC5 pre-
mRNA that may originate an independently regulated
intron segment [38].
In addition, we determined that the genomic region
upstream of the ncHDAC5 putative TSS and within its
transcription locus is evolutionarily conserved in verte-
brates (Figure 3F). On the other hand, CpG islands were
not detected upstream or within the ncHDAC5 genomic
region (Figure 3F). There was no evidence that ncHDAC5
is a precursor of small RNAs, because no miRNA or
snoRNA with sequence identity to the lncRNA were
found in the public databases [62,63].
Finally, the ncHDAC5 showed five distinct regions
(ranging from 79 to 114 nt in length) where evolutionar-
ily conserved secondary structures were predicted by
RNAz tool (P > 0.5) (Additional file 6: Table S4B); the
most significant secondary structure (P = 0.99) covering
110 nt is transcribed in the antisense direction, and its
predicted folding is shown in Figure 3G.
Functional associations of intronic antisense lncRNAs and
protein-coding mRNAs in RCC
To extend the study of intronic antisense lncRNAs
expressed in RCC we used a custom-designed 44 k oli-
goarray platform that allowed the detection of strand-
specific expression in the intronic loci, by containing
10,525 single-stranded 60-mer oligonucleotide probes,
essentially interrogating 15-fold more intronic loci than
the array that we had used in the previous experiments.
We focused on the antisense intronic lncRNAs, exclud-
ing the sense intronic ncRNAs from further analyses, be-
cause the antisense messages are admittedly transcribed
independently from the protein-coding genes in the loci.
The majority of RCC cases interrogated using this 44 k
oligoarray were the clear cell subtype studied above (14
cases), and there were also papillary (2 cases) and chro-
mophobe (1 case) subtypes; these seventeen tumor sam-
ples were randomly split into four pools, as indicated in
Additional file 7: Table S5.
We identified 4303 antisense intronic lncRNAs as
expressed in RCC from 3102 protein-coding gene loci
(Additional file 8: Table S6). To verify their predicted
noncoding status, we used the software Coding Potential
Calculator (CPC) [64]. The CPC analysis pointed to a
lack of protein coding potential of nearly all intronic anti-
sense transcripts tested (4293/4303, 99.8%) (Additional
file 8: Table S6). This finding indicates that the vast
majority is indeed noncoding RNAs. To better describe
our set of lncRNAs, it was cross-referenced with RefSeq
annotations at the UCSC database (http://genome.ucsc.
edu/). We found six RNAs (0.14%) already annotated as
noncoding RNAs (Additional file 8: Table S6), indicating
that the vast majority of our set are novel unannotated
intronic antisense ncRNAs. To investigate if these are pos-
sible precursors of small RNAs, we cross-referenced the
genomic coordinates of our 4303 antisense lncRNA set to
snoRNA [62] and microRNA [63] datasets. Because micro-
RNA precursor lengths are on average >1,000 nt, we ex-
tended the lncRNAs genomic coordinates by 1 kb at both
the 3′- and 5′- ends. Only one ncRNA out of all 4303
ncRNAs mapped to a small RNA, namely U99 (Additional
file 8: Table S6), suggesting that this set of antisense
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lncRNAs expressed in RCC has a diverse function other
than being precursors of small RNAs.
Next, we investigated the patterns of co-expression of
the antisense lncRNAs and the mRNAs expressed in cis
(both expressed from the same locus) or in trans (ex-
pression of an antisense lncRNA correlated to the ex-
pression of mRNAs from other loci). We started with
the 4303 intronic antisense lncRNAs expressed in renal
cancer, and analyzed their expression pattern in RCC
and in three human tissues previously studied by our
group with the same microarray platform [40], namely
normal liver, prostate tumor and kidney nontumor sam-
ples. For the cis-correlation analysis, Spearman correl-
ation was calculated using the expression levels of each
antisense lncRNA and the mRNA expressed from the
same locus measured across RCC and the three tissue
types. A total of 3467 (out of 4303; 81%) lncRNAs/
mRNAs from the same locus were considered in the
analysis because they were detected in all tissues. We
identified a direct or inverse cis-correlation for the ex-
pression in the four tissues of 929 (929/4303 =22%) anti-
sense lncRNA/mRNA from the same locus (Figure 4A
and Additional file 8: Table S6). These lncRNAs/mRNAs
had significant (p <0.05) correlation coefficients in the
range −0.5 > ρ >0.5.
Next, we performed a gene enrichment analysis to iden-
tify Gene Ontology (GO) terms that were overrepresented
among protein-coding genes whose expression was signifi-
cantly cis-correlated to the expression of intronic antisense
lncRNAs from the same loci. We found the term “bio-
logical regulation” as the most enriched general term (p <
5.00E-7) followed by “cellular component organization”,
“cellular process”, “developmental process”, “reproduc-
tion” and “death” (Figure 4B). It is noteworthy that among
all GO enrichment terms, the term “regulation” is present
in 40% (61/152). Among the enriched “biological regulation”
processes are the “regulation of cell growth”, “regulation
of cell proliferation”, “regulation of cell communication”,
the “positive regulation of protein metabolic process” and
the “negative regulation of transcription from RNA pol II
promoter” (Additional file 9: Figure S3).
Considering only the positive cis-correlation for GO
enrichment analysis, 58 GO terms are enriched, and 98%
(57/58) of those are present in the complete cis-correlation
analysis. Regulation of cellular process is the most fre-
quent GO term. Regulation is present in 34% (20/58) of all
GO enriched terms. Considering only the negative cis-
correlation for GO enrichment analysis, 60% (32/53) are
related to regulation, being regulation of metabolic
process the main enriched GO term. Of those, 32% (17/53)
are exclusive GO terms that were not present in the
complete cis-correlation analysis. All GO-enriched terms
are shown in detail in Additional file 9: Figure S3 and
listed in Additional file 10: Table S7.
We observed with the Spearman analysis described
above that the expression of the majority of the anti-
sense lncRNAs (78%) was not cis-correlated to the ex-
pression of the mRNA transcribed in the same locus
(Figure 4A). Therefore, to investigate subsets of intronic
antisense lncRNAs that were trans-correlated, we per-
formed a Spearman correlation analysis comparing the
level of each lncRNA with the expression levels of
mRNAs from all genomic loci represented in the 44 k-
array, again using the data from RCC and from the three
other human tissues [40]. To favor the identification of
biologically relevant regulatory RNAs, only the 20%
most abundant intronic antisense lncRNAs in RCC (n =
860) were used for the trans-correlation analysis. A total
of 693 antisense lncRNAs (out of 860; 81%) and 5438
mRNAs that were detected in all tissues were used to
calculate a matrix of trans correlations. We identified
inverse or direct high trans-correlation values (−0.7 ≥
ρ ≥0.7) between all 693 antisense lncRNAs and at least
one of 5293 mRNAs from different genomic loci (out of
5438 mRNAs) (Additional file 11: Figure S4), which corre-
sponds on average to the expression level of one antisense
lncRNA being trans-correlated to the expression of 7.6
different expressed mRNAs in the four tissues studied.
Next, using Genomica software and the matrix of
trans correlation as input, we constructed a module map
of antisense lncRNAs versus GO enriched terms among
the trans-correlated mRNAs (Figure 4C). We identified
106 intronic antisense lncRNAs positively and negatively
associated to 51 enriched GO terms (p < 0.05, Bonferroni
correction). Among those GOs with correlated lncRNAs
are “response to stress”, “inflammatory response”, “meta-
bolic process”, “immune response”, “RNA processing”,
“response to stimulus”, and “ion transporter activity”
(Figure 4C; Additional file 10: Table S7D).
Intronic antisense lncRNAs expressed in RCC are enriched
in genomic marks that suggest an independent gene
expression regulation
To determine if regulatory elements occur at and are fre-
quent in the genomic regions of the intronic antisense
lncRNAs expressed in RCC, we compared the overlap dis-
tribution of genomic coordinates of these lncRNAs with
datasets of genomic coordinates of Cap Analysis Gene
Expression (CAGE) tags from PolyA+ RNA-derived librar-
ies from 35 cell lines [65], of predicted CpGs islands [66],
HMM active promoter prediction [59] and of ChIP-seq
data for RNA Polymerase II binding site [65] and histone
modification marks [59,60,67]. A random sequences set
was used as control. Because the transcripts we had identi-
fied as expressed in RCC are mainly polyA+, given that
our microarray experiments were performed using oligo-
dT primed cDNA synthesis and labeling, we chose to use
the PolyA+ RNA-derived ENCODE datasets.
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A significant association of CAGE tags with the puta-
tive antisense lncRNA TSSs was identified (Figure 5A).
This finding is analogous to the reported presence of the
5′ cap modification at the TSS of lincRNAs [29]. CAGE
tags are mostly present within the first kb from the
known TSS of antisense lncRNAs and of mRNAs. This
distribution is statistically different (Kolmogorov-Smirnov
(KS) test p < 0.001) from that observed for the control
random sequences set (Figure 5A). Next, we identified a
significant association (KS test p < 0.001) between the
predicted TSS of intronic antisense lncRNAs and CpG
islands (Figure 5B), active promoter HMM predicted
regions (Figure 5C) or RNA polymerase II binding site
(Figure 5D).
We also identified a significant association between
transcriptional activation histone marks H3K27ac
(Figure 5E) or H3K4me1 (Figure 5F) and the putative TSSs
of the intronic antisense lncRNAs (KS test p < 0.001); the
analysis was performed with data from seven different
human cell lines [59]. We looked at histone modification
marks in renal tissue datasets [60], and found that the
promoter-associated H3K4me3 mark (Figure 5G) and
the activation-associated H3K36me3 mark (Figure 5H)
showed a statistically significant higher frequency (KS test
p < 0.001) at the genomic regions of the intronic antisense
lncRNAs transcribed in RCC. The transcriptional repres-
sive H3K27me3 mark was not identified in the renal tissue
public data [60] at the TSSs of the antisense lncRNAs
Figure 4 Functional associations of intronic antisense lncRNAs expressed in RCC. (A) Cis-correlation analysis. Histogram of Spearman
correlation values calculated using the expression levels of intronic lncRNAs and mRNAs expressed in 4303 gene loci, across RCC and three other
human tissues (normal liver, prostate tumor and kidney nontumor). (B) GO enrichment analysis of the mRNAs correlated in cis with the lncRNAs
from the same loci (Spearman correlation −0.5 > ρ >0.5; p <0.05; see red broken lines in panel A). Color scale indicates increasingly higher
statistical significance of enriched GO terms: Yellow, p = 0.05; Dark orange, p <0.0001. (C) Trans-correlation analysis. Module map of lncRNAs and
GO enriched terms among trans-correlated mRNAs. Analysis was performed with the 20% most abundant lncRNAs (columns) that showed
Spearman correlation values in the ranges −0.7≥ ρ ≥0.7 between its expression level in RCC and in three other human tissues (normal liver,
prostate tumor and kidney nontumor) and the expression of mRNAs outside the host locus (correlation in trans; p <0.05); GO terms significantly
enriched among trans-correlated mRNAs are shown in the rows (p <0.05 with Bonferroni correction). Colors indicate if the majority of the mRNAs
within that GO is directly (yellow) or inversely (blue) correlated with the lncRNA. A black entry indicates no significant enrichment. The lists of GO
enriched terms and of mRNAs belonging to each term for panels 4B and 4C are given in Additional file 10: Table S7.
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Figure 5 Regulatory genomic marks associated with intronic antisense lncRNAs expressed in RCC. Red lines show the abundance
distribution of CAGE tags (A), CpG islands (B) and histone marks (C-G) within a distance of 5 kb from the TSSs of the intronic antisense lncRNAs
expressed in RCC. For comparison, abundance distribution of these marks for an equal number of protein-coding mRNAs (black lines), or for a
control set of randomly selected intronic genomic sequences with the same length of the expressed lncRNAs (grey lines) were calculated.
(A) CAGE tags, (B) CpG islands, (C) active promoter HMM predictions, (D) RNA polymerase II binding sites, (E) transcriptional activation histone mark
H3K27ac, (F) transcriptional activation histone mark H3K4me1, (G) promoter-associated histone mark H3K4me3, and (H) activating-associated histone
mark H3K36me3. In parentheses are the significance p-values of Kolmogorov-Smirnov (KS) statistical tests for differences in abundance distribution in
relation to the control random set.
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(data not shown); this was expected because these lncRNAs
are the ones detected as expressed in RCC.
Intronic antisense lncRNAs expressed in RCC are
specifically expressed in other tissues
To investigate the tissue-specificity of the 4303 intronic
antisense lncRNAs expressed in RCC we cross-referenced
the genomic coordinates of our dataset with the coordi-
nates of RNA-seq reads from nine human tissues [68]
(Figure 6A) and with RNA-seq data of strand-oriented
libraries from seven human cell lines [69] (Figure 6B). In
the human tissues analysis, we found that 15% of the anti-
sense lncRNAs (628 out of 4303) were detected only in
RCC (Figure 6A). A total of 3675 lncRNAs were detected
in at least one of the nine tissues (Figure 6A). In the
strand-oriented data from human cell lines, we found that
71% of the antisense lncRNAs (3064 out of 4303) were
detected only in RCC (not shown). A total of 1239
lncRNAs (out of 4303, i.e. 29%) were detected in at least
one out of the seven cell lines (Figure 6B). A similar well-
marked expression pattern was observed for protein-
coding genes across tissues and cell lines in RCC
(Additional file 12: Figure S5), with the notable exception
that the majority of these protein-coding genes (94%, i.e.
5296/5632) were detected in at least one of the strand-
oriented RNA-seq data from the human cell lines.
Intronic antisense lncRNAs expressed in RCC are
evolutionarily conserved
Expression conservation was evaluated by comparing the
intronic antisense lncRNAs detected in RCC with cDNAs
expressed in 15 vertebrate species that are compiled in the
TransMap cross-species alignments [70]. This analysis re-
vealed that 60% of the intronic antisense lncRNAs
Figure 6 Tissue expression pattern of intronic antisense lncRNAs. (A) Heat map representing the abundance of 4303 RCC-expressed intronic
antisense lncRNAs (columns) across other nine human tissues (rows) based on public RNA-seq data [68]. Color intensity represents fractional
density expression of each lncRNA across all tissues (see Material and methods for details). There are 628 lncRNAs (out of the 4303; i.e. 15%) at
the right hand side of this panel that were exclusively detected in RCC. (B) Heat map indicating the presence (red) or the absence (white) of
1239 RCC-expressed lncRNAs (columns) in seven human cell lineages (rows) from public strand-oriented RNA-Seq libraries [69]. These 1239
intronic antisense lncRNAs represent 29% of the 4303 lncRNAs detected in RCC; the other 3064 lncRNAs (71%) were detected exclusively in RCC,
not in the cell lines (not shown). Expression data was hierarchically clustered.
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expressed in RCC (2594 out of 4303) are expressed in at
least another species (Figure 7A). There is a higher pro-
portion of expression conservation across the species in
the lncRNA dataset compared with 10 control random
sets of sequences extracted from the human genome
(Fisher test p < 0.0001) (Figure 7B).
To further explore the conserved pattern of expression
of these 4303 intronic antisense lncRNAs, we compared
them with the 4858 introns harboring functional anti-
sense ncRNAs recently identified by large scale RNA-seq
in the mouse lung in response to inflammation [38]. A
total of 1220 intronic regions could unequivocally be
mapped to human genomic loci, and their corresponding
coordinates were cross-referenced to the coordinates of
the 4303 intronic antisense lncRNAs expressed in RCC.
A total of 53 lncRNAs were detected as expressed in
common both in mouse and in human, at syntenic loci,
and the genomic coordinates are given in Additional file
8: Table S6. The length of overlap was in the range of 30
to 1228 bases among the 53 lncRNAs (Additional file 8:
Table S6). We found a significantly higher proportion of
expression overlap between mouse and RCC (53 out of
4303 intronic loci expressed in RCC) compared with a
control random set of lncRNA sequences extracted from
the subset of lncRNAs with no evidence of expression in
RCC, among the entire set of intronic antisense
lncRNAs probed in the 44 k array (overlap of 23 out of
4303 random intronic loci with no evidence of expres-
sion in RCC) (Fisher test p <0.001).
Comparison of the genomic coordinates of the 4303
intronic antisense lncRNAs expressed in RCC with those
from conserved DNA elements identified in vertebrates,
placental mammalians and primates (PhastCons, [61])
revealed a significant enrichment as compared with a
random set of genomic sequences used as a control
(Fisher test p < 0.0001) (Figure 7C). RNAz analysis [71]
predicted secondary structure conservation for 131 in-
tronic antisense lncRNAs (Additional file 8: Table S6
and secondary structures at http://verjo101.iq.usp.br/
sites/projetosLab/fachel/structures/results.html). There are
73 antisense lncRNAs in common to all three conserva-
tion analyses described above (Figure 7D).
Discussion
In the present study, we determined the expression pat-
tern of a collection of intronic lncRNAs in clear cell RCC
Figure 7 Conservation analysis of intronic antisense lncRNAs expressed in RCC. (A) TransMap cross-species cDNA alignments in 15 vertebrate
species (rows; species common name and library version in brackets) of 2594 intronic antisense lncRNAs expressed in renal tissue and with conserved
expression in at least one species (green dashes show expression conservation). (B) Bar graph of the TransMap analysis showing a higher proportion of
expression conservation of the lncRNA dataset compared with a random sequence dataset (Fisher test p <0.0001). (C) DNA sequence conservation of
antisense lncRNAs within vertebrates, placental and primates groups. Black bars show the number of lncRNAs, and gray bars the number of random
genomic regions, overlapping PhastCons elements (see Material and methods for details). Asterisks show statistically significant differences in the
number of overlapping elements (Fisher test p <0.0001). (D) Venn Diagram of three different conservation analyses of the intronic lncRNAs expressed
in RCC: RNAz predicted secondary structure conservation for 131 lncRNAs, PhastCons DNA sequence conservation for 3241 lncRNAs and TransMap
expression conservation for 2594 lncRNAs.
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patients and identified candidates that might play a role in
renal cancer biology. There are only two published studies
of lncRNAs in RCC so far: our previous study [49] that
identified for the first time seven intronic lncRNAs differ-
entially expressed in RCC among a protein-coding gene
signature; and the work of Yu et al. that identified 626
lncRNAs differentially expressed between tumor and non-
tumor tissue in 6 clear cell RCC patients. These authors
used a microarray that essentially probed intergenic
lncRNAs [50] and they validated by qPCR four transcripts,
being three intergenic lncRNAs (ENST00000456816,
X91348 and NR_024418); one was not a lncRNA, but
rather the non-coding 3′-end portion of the TMEM72
protein-coding gene (BC029135).
We identified 29 lncRNA transcripts originated from
intronic regions and additionally 11 from intergenic re-
gions, resulting in a ccRCC-associated gene expression
profile comprised exclusively of lncRNAs. From this set,
there are three intronic lncRNAs from the ACTN4,
HDAC5 and SLC2A1 loci identified as down-regulated
both here and in our previous study [49] using the same
microarray platform. This partial overlap (3 out of the 6
intronic lncRNAs described in Ref. [49]) is possibly re-
lated to the more stringent statistical criteria presently
used, namely the leave-one-out approach that minimizes
the contribution of each individual patient to the set of
significantly altered genes when a small patient cohort is
analyzed [51,72].
The comparison of our 217 protein-coding gene profile
with nine published studies of differentially expressed
protein-coding genes in ccRCC [5,49,52-58] verified that
the vast majority (83%) of the genes in common (142/170)
presented a concordant pattern of expression (Table 2),
thus validating the present analysis as representative of the
ccRCC biology.
Besides a set of intronic lncRNAs potentially involved
in carcinogenesis, the present study identified a set of 26
intronic lncRNAs that were correlated to the survival of
ccRCC patients. From this set, eight lncRNAs were iden-
tified as altered in both the malignancy and the survival
outcome expression profiles, and they are transcribed
from the loci: ACTN4, CSNK1D, DNAJC3, GIGYF2,
HDAC5, PTPN3, RAB25 and VPS13B. To the best of our
knowledge, this is the first study suggesting lncRNAs as
correlated to the patient survival outcome in RCC. Re-
garding other types of ncRNAs, there are at least two
miRNA expression studies that had identified candidates
correlated with patient survival outcome in RCC [21,73].
The lncRNAs identified in the present work may con-
tribute to future studies focusing on lncRNAs as mo-
lecular markers in RCC oncology.
There are few examples of well-characterized lncRNAs
associated with RCC. The lincRNA GAS5 is a well de-
scribed tumor suppressor in breast cancer [74], and very
recently it was described in prostate cancer cell lines [75]
and in RCC [76]. A decreased expression of the lincRNA
GAS5 is associated to RCC genesis and progression, and
its overexpression is associated to cell proliferation inhib-
ition and apoptosis induction [76]. Another example in-
cludes two antisense lncRNAs at the 5′ (5′aHIF-1α) and
3′ (3′aHIF-1α) ends of the human HIF-1α gene that are
expressed in human kidney cancer tissues [77].
In cancer, there are a few examples of the mechanisms
of action of intronic lncRNAs. Our group described the
intronic antisense and unspliced lncRNA ANRASSF1
that causes the epigenetic in cis downregulation of the
tumor suppressor RASSF1A gene and increases cell pro-
liferation [43], and its expression is higher in prostate
and breast cancer cell lines compared with nontumor
cells [43]. Guil et al. [42] identified that overexpression
of the sense intronic lncRNA from the SMYD3 locus
caused the epigenetic in cis regulation of SMYD3 and a
decrease in colorectal cancer cell line proliferation [42].
The androgen-regulated intronic antisense lncRNA
CTBP1-AS [44] appears to be a key antisense ncRNA
that acts as both cis- and trans-regulator of gene expres-
sion. The CTBP1-AS lncRNA promotes prostate cancer
growth through sense-antisense repression of the tran-
scriptional co-regulator CTBP1 transcribed from the
same locus (cis-regulation), and through a global epigenetic
regulation of tumor suppressor genes (trans-regulation)
[44]. In fact, the intronic and also the intergenic lncRNAs
play important epigenetic roles in cancer [78].
We decided to study the intronic lncRNA ncHDAC5
in more detail because it showed a decreased expression
in ccRCC tumor compared with nontumor tissue that
was confirmed by qPCR, and because its increased expres-
sion seems to be associated to the cancer-related death
after surgery in RCC, as suggested by our patient survival
outcome analysis. We determined that ncHDAC5 is an
unspliced long transcript (1.7 kb long), detected in the
antisense and sense directions relative to the protein-
coding gene histone deacetylase 5 (HDAC5). It has a short
half-life of 42 min compared with other well studied
lncRNAs, such as Air, Kcnq1ot1 and Xist, which have half-
lives of 2.1, 3.4 and 4.6 h, respectively [79], with an evolu-
tionarily conserved secondary structure. The absence of
association between the expression of ncHDAC5 and the
protein-coding mRNA HDAC5, determined by qPCR and
by a meta-analysis of five kidney cancer gene expression
studies (Table 1), suggests a locus independent function,
with the ncHDAC5 possibly acting in trans to regulate
protein-coding genes (see the discussion on trans regula-
tion below). Unfortunately, a probe for this ncHDAC5 was
not present in the 44 k oligoarray that was used for asses-
sing the trans correlation of expressed lncRNAs/mRNAs,
and it was not possible to determine the ncHDAC5 candi-
date target mRNAs by our co-expression analysis.
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An in silico analysis indicated the presence of RNA
Pol II binding and of the histone marks H3K27ac and
H3K4me3 at ~1.5 kb upstream of the putative TSS of an
antisense ncHDAC5 transcript in the HDAC5 locus.
Considering the lack of methylation marks in the vicinity
of the lncRNA, this observation opens an interesting
possibility of transcriptional regulation of the antisense
lncRNA ncHDAC5 by histone acetylation. It is in line
with the result recently described for the lncRNA-LET, a
lncRNA generally downregulated in carcinomas, that
was shown to be repressed by histone deacetylase 3 under
hypoxic conditions [80]. Interestingly, the transcriptional-
activation-associated H3K4me1 and H3K27ac histone
modification marks at human enhancers have been de-
scribed as related to a cell-type specific protein-coding
gene expression [81]. The TSSs at the lncRNA ncHDAC5
locus as well as at the loci of the other intronic antisense
lncRNAs expressed in RCC were enriched with both his-
tone marks, in agreement with the fact that the intronic
lncRNAs tend to have a tissue-specific pattern of expres-
sion [9], thus supporting a possible cell-type specific
modulation of intronic antisense lncRNAs by histone
methylation and acetylation.
Because the intronic lncRNAs revealed a promising
well-defined pattern of altered expression in RCC, and
there is scarce data about this ncRNA class in RCC, we
extended our study to the antisense intronic lncRNAs
using a custom-designed strand-specific 44 k-element
microarray that contained 15-fold more probes for
lncRNAs than the 4 k-array that we had previously used.
With this new platform, we identified 4303 antisense in-
tronic lncRNAs expressed in RCC; we found that 4061
out of the 4303 antisense lncRNAs have not been previ-
ously reported in the Yu et al. study [50] as being
expressed in RCC, which is in agreement with the fact that
Yu et al. [50] used a microarray that probed mostly inter-
genic lncRNAs. In addition, only six lncRNAs are already
annotated as RefSeq noncoding RNAs (Additional file 8:
Table S6). In fact, the most recent catalog of human in-
tronic lncRNAs comes from the GENCODE project [9],
which documented the intronic lncRNAs expressed in 12
human normal tissues. Thus, the present study is a contri-
bution towards the generation of a catalog of intronic anti-
sense lncRNAs expressed in renal cancer.
The set of 4303 intronic antisense lncRNAs expressed
in renal cancer identified in the present study probably
has diverse functions, other than being precursors of
small RNAs, because only one lncRNA mapped to a
known small RNA sequence (U99, Additional file 8:
Table S6). We found that 22% of the intronic antisense
lncRNAs have expression levels in RCC, normal kidney,
normal liver and tumor prostate that are correlated in
cis to the expression levels of the mRNA from the same
locus. These lncRNAs correlated in cis are transcribed
from loci enriched with genes related to regulation, in-
cluding the term “Regulation of Transcription from RNA
polymerase II”, as seen when analyzing together the posi-
tively and negatively cis-correlated antisense lncRNA/
mRNA as well as when analyzing only the positively cis-
correlated transcripts (Additional file 9: Figure S3). Our
group has described a similarly enriched GO term when
analyzing the host gene loci of the 30% most abundant in-
tronic antisense lncRNAs, without considering any expres-
sion correlation between the ncRNAs and the mRNAs
[40]. Now we point to this GO term enrichment for those
loci expressing the antisense lncRNAs and the mRNAs in
a correlated manner, reinforcing the suggestion that the
lncRNAs might cis-regulate the expression of the genes in-
volved in “Regulation of Transcription” and/or that the
antisense lncRNAs and the mRNAs might be controlled
by a similar regulatory event in these loci.
We found that the expression of the majority of the
intronic antisense lncRNAs was not correlated to the ex-
pression of the mRNA from the same locus, and those
are most likely regulated in an independent way of the
mRNAs. Among these, we identified a set of antisense
lncRNAs whose expression in RCC, normal liver, pros-
tate tumor and kidney nontumor tissues was positively
or negatively correlated in trans to the expression levels
of sets of mRNAs belonging to enriched GO terms such
as “Inflammatory response” and “Response to stress”;
these protein-coding genes may be related to the cellular
renal cancer context, and the correlated lncRNAs are
candidates to be acting in trans to regulate their expres-
sion. The present GO analyses support the proposal that
ncRNAs might be part of a fine-tuning regulatory net-
work in the cells [82-84].
Our computational analysis has generated a list of 4303
intronic antisense lncRNAs expressed in RCC (Additional
file 8: Table S6) that includes subsets associated to CpG
islands, CAGE tag marks, RNA pol II binding site,
promoter-associated chromatin marks, tissue-specificity
and evolutionary conservation. The set of 53 intronic anti-
sense lncRNAs expressed in common at syntenic loci in
human and mouse represent good candidates for subse-
quent in-depth biological follow up work; the low overlap
may be related to the known tissue-specific expression of
lncRNAs [8,41] and to the known tissue-pattern of expres-
sion conservation among different species [85], consider-
ing that StLaurent et al. [38] used mouse lung tissues and
we have used human kidney tumor tissues. Although
lncRNAs are much less conserved than other functional
ncRNAs such as miRNAs and snoRNAs [86], there is
good evidence in the literature regarding the presence
among the intronic lncRNAs of evolutionarily conserved
regions spanning 400 nt or more [39,85,87]. Our recent
work with pancreatic cancer has identified an enrichment
of conserved regions within intronic and intergenic
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lncRNAs [46], and here we extend the identification of
conserved regions to the intronic antisense lncRNAs
expressed in RCC. Although some of the introns could
contain regulatory sequences, or yet undiscovered coding
exons overlapped by the intronic RNAs, thus accounting
for part of the enrichment signal, the observed primary
and secondary structure conservation suggests that the
intronic lncRNAs are under the influence of evolutionary
constraints.
In silico approaches have been successfully used to
characterize sets of lncRNAs expressed in other tissues or
cell lineages [9,28,29,46,69]. Here, we used them to obtain
new data indicating that intronic lncRNAs should not be
regarded simply as by-products of random transcription
[38], but rather as a diverse and heterogeneous class of
cellular transcripts that may comprise yet uncharacter-
ized regulatory RNAs. The intronic lncRNAs identified
here as expressed in RCC may have several mechanism of
action, both positively and negatively regulating gene ex-
pression, and as a consequence, may constitute a promis-
ing starting point for further functional investigations.
Material and methods
Patient tissue material
Individual tissue samples were analyzed for gene expres-
sion with a 4 k-element array described below. The 29
tissue samples consisted of 18 primary renal tumors and
11 matched adjacent nontumor tissue from 18 patients
who underwent radical nephrectomy for clear cell RCC
at the Hospital of the Instituto Nacional de Cancer
(INCa), Brazil. Ethical approval for the study was
granted by INCa institutional review under the ID num-
ber 2701; all patients have signed an informed consent.
Each sample was frozen and stored in liquid nitrogen
immediately after surgery. A fraction of each sample was
processed for histopathological diagnoses. A second in-
dependent histopathological diagnosis of each case was
confirmed by a reference pathologist (GV) who belongs
to the INCa staff. Histologically normal renal tissue frag-
ments were collected from a distant portion of the surgi-
cally removed kidney. Clinical and anatomopathological
patient data are detailed in Additional file 1: Table S1.
The malignancy gene expression profile was identified
with the 11 paired tumor and adjacent nontumor patient
samples. Identification of the survival gene expression
profile was performed with 16 tumor samples (nine tu-
mors from the paired samples mentioned above for
which the survival information was available, plus seven
tumor samples for which only the survival information
and not the paired nontumor tissue was available). Pa-
tient survival was recorded from the date of nephrec-
tomy to the date the patient died or was last known
alive (follow-up ranged from 60 to 66 months) and pa-
tients were identified as alive without disease (n = 8) or
dead from cancer (n = 8). Kidney tissue samples expres-
sion was also measured with a 44 k-element oligo-array
described below using 4 pools of nontumor (N) samples
from 17 RCC, and 4 pools of the corresponding 17 paired
tumor (T) samples. They comprise all 11 tumor-
nontumor paired clear cell renal cell carcinoma (ccRCC)
cases that were analyzed individually with the 4 k platform
(Additional file 1: Table S1), plus other three ccRCC cases,
two papillary RCC cases and one chromophobe RCC case.
Clinical and anatomopathological data of these patients
are detailed in Additional file 7: Table S5.
Microarray platforms design
The custom 4 k-element microarray platform previously
described by our group [45] is composed of 3355 unique
cDNA probes from the Cancer EST Sequencing Project
[88] spotted in duplicate (average length of 600 bp), plus
positive and negative controls; 2371 probes interrogate
cancer-related protein-coding genes compiled from the
Entrez, OMIM and CGAP databases; an additional set of
984 probes was randomly sampled from cDNA clones
whose sequences showed no similarity to protein-coding
genes in GenBank, of which 722 are putative noncoding
transcripts that map to intronic regions of known genes,
188 map to intergenic regions of the genome and 74
ESTs map to known RefSeq lincRNAs (a total of 262 pu-
tative lincRNAs). Probes were mapped and annotated
according to the hg 19 assembly of the human Genome
Reference Consortium (GRC) based on the RefSeq and
UCSC datasets. The 4 k-array description is deposited in
Gene Expression Omnibus (GEO) data repository under
accession number GPL3985.
The custom 44 k-element oligoarray platform designed
by our group and manufactured by Agilent Technologies
was previously described [40]. Essentially, the array is
comprised of strand-specific 60-mer oligonucleotide
probes designed for both the plus or the minus genomic
strands of 6,258 totally intronic noncoding (TIN) RNA
loci and 4,267 partially intronic noncoding (PIN) RNA
loci with evidence of transcription from dbEST [40], for
a total of 21,050 strand-specific probes that interrogate
both strands of 10,525 unique intronic loci within 6,361
unique protein-coding spliced human genes; the latter
are represented by unique probes from the Agilent
Whole Human Genome Oligo Microarray. Probes were
mapped and re-annotated according to the hg 19 assem-
bly of the human Genome Reference Consortium (GRC)
based on the RefSeq and UCSC datasets. The 44 k-array
description [40] and the re-annotation are deposited in
the GEO repository under accession number GPL9193.
Microarray experiments
Total RNA was isolated from frozen tissues with TRIzol
reagent (Life Technologies) according to the manufacturer
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recommendations, followed by DNase I treatment for
20 min and purification with the RNeasy Mini kit
(Qiagen). Purified total RNA was quantified in the Nano-
Drop ND-1000 spectrophotometer (Thermo Fisher Scien-
tific), and checked for integrity with the 2100 Bioanalyzer
(Agilent Technologies).
For the 4 k-element microarray assays, complementary
RNA (cRNA) for each of the 29 samples (Additional file
1: Table S1) was obtained by linear amplification follow-
ing the Wang protocol method [89]. Briefly, cDNA for
each sample was synthesized from 3 μg total RNA using
an oligo-dT primer incorporating a T7 RNA promoter
and Superscript III Reverse Transcriptase (Invitrogen).
Double-stranded cDNA was obtained using a template
switch oligo primer with the Advantage cDNA Polymer-
ase mix kit (Clontech). Subsequently, complementary
RNA (cRNA) was generated in vitro with MegaScript T7
RNA Polymerase (Ambion). A second round of amplifi-
cation was performed with 1 μg of cRNA obtained in
the previous step, in the presence of amino-allyl-UTP
(Ambion). Coupling of amino-allyl-cRNA with Cy5 re-
active dye was performed (Amersham Pharmacia Bio-
tech). Labeled cRNAs were purified using RNeasy Mini
kit (Qiagen) and hybridized to a total of 29 microarray
slides followed by washing and drying in an automated
Hybridization Station (GE Healthcare) according to the
manufacturer recommendations. Array images were ac-
quired with a Generation III Array Scanner (GE Health-
care). Data were extracted from the scanned images with
ArrayVision 6.0 software (GE Healthcare).
For the 44 k-element microarray assays, four pools of
tumor (T1 to T4) or nontumor (N1 to N4) paired sam-
ples from 17 patients were assembled (three pools of 4
samples, one pool of five samples) as detailed in
Additional file 7: Table S5 by mixing equal amounts of
total RNA. Total RNA pool (300 ng) was used as tem-
plate for the amplification of poly(A) RNA by the T7-
RNA polymerase with the Low RNA Input Fluorescent
Linear Amplification kit (Agilent Technologies), which
generated Cy5- or Cy3-labeled cRNAs. A total of four
array slides were hybridized with 750 ng each of Cy3-
and Cy5-labeled cRNAs, in the following arrangement:
Cy3 2T x 1N Cy5; Cy3 2N x 1T Cy5; Cy3 4T x 3N Cy5;
Cy3 4N x 3T Cy5. Hybridization was performed with
the Agilent in situ Hybridization kit-plus, as recom-
mended by the manufacturer. The slides were washed
and processed according to the Agilent Oligo Micro-
array Processing protocol and were scanned on a
GenePix 4000B scanner (Molecular Devices). To ex-
tract intensity data from the scanned images we used
the Agilent Feature Extraction software (Agilent
Technologies). All the above microarray data are de-
posited at the GEO repository under the accession
number GSE40914.
Microarray data analyses
For the 4 k-element microarray, a gene was considered
expressed if its probe intensity was higher than the local
background intensity and above the threshold defined by
the average intensity plus three standard deviations of a
set of plant-derived negative control cDNA probes (GE
Healthcare). Probes were excluded from further analyses
when they were detected in less than 90% of the arrays
in any of the two groups, i.e. nontumor or tumor for the
malignancy analysis; or alive or dead from cancer for the
survival analysis. The raw intensities were normalized by
the quantile method [90].
For the 4 k-element microarray malignancy study,
tumor/nontumor log2 ratios were calculated followed by
a supervised one-class statistical analysis with the Sig-
nificance Analysis of Microarrays (SAM) tool [91] with
1000 permutations to identify transcripts that were
differentially expressed in eleven clear cell RCC and ad-
jacent nontumor tissue. A sample leave-one-out cross-
validation was performed [72,92]. Essentially, one sample
was removed at a time, and each time a new set of sig-
nificantly altered genes was determined with SAM using
the remaining ten samples. This procedure was repeated
for each of the matched tumor/adjacent nontumor tissue
samples; a false discovery rate (FDR) cutoff ≤5% was
used in all eleven leave-one-out datasets. This approach
was used to minimize the contribution of each individual
patient sample to the set of significantly altered genes
[51]. The final gene profile is comprised of altered genes
present in 100% of the leave-one-out datasets plus a 1.5-
fold minimal change criterion. For the 4 k-element
microarray survival study: a two-class unpaired Signifi-
cance Analysis of Microarrays (SAM) analysis (FDR
<10%) [91] combined with the Golub’s discrimination
score analysis (p < 0.01) [93] was used for identifying
transcripts expressed in clear cell RCC samples that
were significantly correlated with the patient survival
outcome. Only those genes found in common in both
analyses were used to compose a profile of genes corre-
lated to the outcome. The 16 patient samples were or-
dered in the heat-maps according to the correlation of
their gene expression profiles to the average expression
profile obtained from the 8 samples of patients who died
from the disease within the 5-year follow-up after
surgery.
For the 44 k-element oligoarray, the transcripts were
considered expressed if the intensity of the spot was
above the mean intensity plus 2 SD of the negative con-
trol spots in 3 out of 4 oligoarrays in one of the two
groups (tumor or nontumor pools). For the intronic
lncRNA transcripts, only the probe mapping to the gen-
ome in the antisense direction relative to the protein-
coding mRNA in the locus was considered for further
analyses.
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Real time RT-PCR
Reverse transcription was performed with 1 μg ali-
quots of DNase I-treated purified total RNA from the
same paired samples that were used in the microarray
experiments, oligo-dT primers and SuperScript III
(Invitrogen) according to the manufacturer’s instruc-
tions. For the relative quantification of transcript
levels, real-time PCR was performed using Power
SYBR Green PCR Master Mix (Applied Biosystems)
on an ABI PRISM 7500 machine (Applied Biosystems)
and the following primers: ncC11orf49, GAGAAGC
AGCGATGACACGAT (Forward), AGAGGAGCAAC
CCTCAGGAAA (Reverse); HDAC5 exon 24/25, TGC
AGCAAAAGCCCAACAT (Forward), AGACCAGCG
GCGAACTTCT (Reverse); ncHDAC5, TATTCTGGA
GTCGCCTGTGCTT (Forward), AACCACAGCCCTA
TTGGTATGC (Reverse); ncRAB31, CCCAGTGAGAG
TGATATTTTGTTATGA (Forward), CCACACCTTC
TTTCTGCCTGTT (Reverse); ncSRPK1, CAAGGGCT
GAGTCCTTTTTCA (Forward), GCAGTGCCTTGCC
CTTATTG (Reverse); HPRT1, TGACACTGGCAAA
ACAATGCA (Forward), GGTCCTTTTCACCAGCA
AGCT (Reverse). The reactions were incubated at
95°C for 15 min, prior to 40 PCR cycles (15 sec at
95°C, 60 sec at 60°C). All reactions were performed
in triplicates in a final volume of 20 μl containing
5 μl of diluted cDNA (1:3) and 800 nM of forward
and reverse gene-specific primers. The gene ex-
pression levels of hypoxanthine phosphoribosyl trans-
ferase 1 (HPRT1) were used as a control to normalize
the measurements. Transcript levels were expressed
following the 2-ΔΔCt method [94], where ΔΔCt =
(ΔCt candidate gene in tumor sample - ΔCt candidate gene in nontumor
sample), with ΔCt = Ct candidate gene - Ct HPRT1.
Orientation-specific reverse transcription
For the orientation-specific cDNA synthesis of ncHDAC5,
ncC11orf49, ncRAB31 and ncSRPK1, 1 μg of purified total
RNA pretreated with DNase I (RNeasy Mini kit, Qiagen)
was used for the reverse transcription reaction. A pool of
RNA from 10 ccRCC samples or from 10 adjacent nontu-
mor tissues samples was used as templates for the cDNA
synthesis. In addition, purified DNaseI-treated total RNA
from tumor kidney cell lineage 786-O or from nontumor
cell lineage RC-124 was used as template. For each sam-
ple, two cDNA synthesis test reactions were performed,
each with 1 μg of total RNA and 500 nM of an oligo-
nucleotide primer complementary to the sequence of the
lncRNA that would be transcribed from either the sense
or the antisense strand within the corresponding loci of
interest (see PCR primers above). SuperScript III Super
Mix kit (Invitrogen) was used according manufacturer’s
instructions. To avoid RNA self-annealing, pre-incubation
of RNA and primer in annealing buffer was performed at
65°C for 10 min followed by the addition of reverse tran-
scriptase in enzyme buffer pre-warmed at 57°C, and the
reaction was incubated for 50 min at 57°C and denatured
at 95°C for 10 min. To verify the absence of self-annealing
or of genomic DNA contamination, a control reverse tran-
scription reaction was performed in parallel without the
addition of primers. These test and control samples were
used for end-point PCR (40 cycles) with the pair of primers
for the corresponding lncRNA, as described above.
RACE-PCR
The Human Fetal Kidney Marathon-Ready cDNA library
(Clontech) and the Marathon cDNA Amplification Kit
(Clontech) were used to perform the 3′- and 5′ RACE-
PCR, following the manufacturer instructions with the fol-
lowing primers: HDAC5_F_GSP_RACE: AGGAGCCCT
GCAGAGAGCACATGG; HDAC5-F_Nested_RACE: AA
GGGGAATCTCCCACCAGCCTGTC; HDAC5-R_GSP_
RACE: GGGGTGCTGCATGTCACCCAGTC; HDAC5-
R_Nested_RACE: TGGAGTCGCCTGTGCTTCCTGTTTG.
RNA stability assay
786-O cells were maintained at exponential growth in
Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% calf serum, penicillin, and streptomycin. Actino-
mycin D was dissolved in DMSO and added to cells at
5 μg/ml. Cells were collected at time 0 h (before actino-
mycin D treatment), 30 min, 1 h, 2 h and 4 h. Total
RNA was extracted and DNAse I treated with RNeasy
Mini kit (Qiagen). cDNA was obtained with SuperScript
III Super Mix kit (Invitrogen) according to manufac-
turer’s instructions. These cDNAs were used for real-
time PCR with the pair of primers for ncHDAC5 as
described above. As a control of the assay, the half-life
for the C-MYC transcript was checked, and the expected
value of ~30 min was obtained.
In silico analyses
To search for protein coding potential of the expressed
antisense lncRNAs in renal cancer we used the Coding
Potential Calculator (CPC) software [64] with default pa-
rameters. To search for RefSeq annotation we mapped the
genomic coordinates of our 4303 antisense lncRNA set to
the RefSeq UCSC database (http://genome.ucsc.edu/). To
identify possible precursors of small RNAs among our set
of lncRNAs we cross-referenced the genomic coordinates
of our 4303 antisense lncRNA set to snoRNA [62] and
microRNA [63] databases, using the sno/miRNA
(wgRNA) UCSC track (http://genome.ucsc.edu/). For the
gene expression meta-analysis we used the Oncomine™
Gene Browser software tool (http://www.oncomine.org).
We investigated the co-expression pattern of intronic
antisense lncRNAs and mRNAs, both in cis (lncRNA
and mRNA from the same locus expressed in a given
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tissue) and in trans (each lncRNA and all mRNAs
expressed in a tissue). First, we created a list of all the
antisense lncRNAs expressed in RCC, and identified
those that were also expressed in other three tissues,
namely nontumor kidney, normal liver and prostate
tumor human tissues (GEO: GSE5452), using the nor-
malized microarray expression data previously obtained
by our group [40].
For the in cis correlation analysis, we used the data
from RCC and the other three tissues and calculated the
Spearman correlation (ρ) using the R software environ-
ment (www.r-project.org), with a cutoff of −0.5 > ρ >0.5
(p <0.05). We used GraphPad Prism software (GraphPad
Softwares, La Jolla, California, USA) to obtain the histo-
gram of Spearman correlation distribution in cis. With
the Bingo software [95], we identified enriched Gene
Ontology terms (p <0.05) considering the set of protein-
coding genes co-expressed in cis (−0.5 > ρ >0.5; p <0.05),
the GO_Biological_Process ontology file and the whole
human genome annotation default Bingo 2.44 version
datasets.
For the trans correlation analysis, we only considered
the top 20% most abundant antisense lncRNAs in RCC.
We constructed a matrix of correlation (using a R script)
of 693 antisense lncRNAs versus 5438 mRNAs expressed
in RCC and in the other three tissues described above.
Next, we selected the lncRNAs most correlated in trans
(cutoff −0.7 ≥ ρ ≥0.7, p <0.05) and used the Genomica
software (http://genomica.weizmann.ac.il) [96] to identify
among the correlated mRNAs the sets of genes (modules)
that were significantly enriched (p <0.05 with Bonferroni
correction) for a specific Gene Ontology term from the
three ontologies, namely Biological Processes, Molecular
Function and Cellular Component.
For transcription regulatory elements and conservation
analyses, we used the BEDTools software package [97]
to compare the genomic coordinates (hg19 GRCh37) of
our antisense lncRNAs dataset with the genomic coordi-
nates of the following datasets available at UCSC Genome
Browser: RIKEN CAGE tags [98] from PolyA + RNA-
derived libraries from 35 cell lines released by the
ENCODE project [65]; predicted CpGs islands [66]; HMM
active promoter prediction [59]; RNA Polymerase II bind-
ing site from the transcription factor ChIP-seq uniform
peaks ENCODE track for 32 human cell lines [65]; ChIP-
seq data of H3K27ac and H3K4me1 DNA binding sites
from seven different human cell lines [59]; H3K4me3,
H3K36me3 and H3K27me3 DNA binding sites from
human renal epithelial cells [60]; RNA-seq data of PolyA +
RNA-derived libraries from 9 tissues [68]; RNA-seq data
of strand-oriented RNA-derived libraries from 7 cell
lines [69].
To test for the statistical significance of the overlap
distribution (see below), we created 10 control datasets
of randomly selected sequences from the entire human
genome matching our set of expressed antisense lncRNA
sequences in number and length. Regulatory elements
mapping up to 1 kb upstream from TSS and 5′UTRs of
RefSeq known transcripts were removed to avoid the
contribution of signals at the start sites of known genes
to the enrichment of regulatory elements at the start
sites of lncRNAs mapping nearby. As a pre-processing
step of the CAGE tag data analysis, only CAGE tags that
presented RPKM (reads per kilobase per million) ≥ 1
were considered for further analysis [69]. We computed
the distance of the closest CAGE tags, CpG islands and
HMM predicted active promoter, RNA Pol II, H3K27ac,
H3K4me1, H3K4me3 and H3K27me3 marks to the pre-
dicted TSSs of our set of 4303 expressed antisense
lncRNAs, 11102 isoforms from 5632 expressed protein-
coding mRNAs, and control sets of 4303 random se-
quences. Regulatory elements distant up to 10 kb of the
sequence initiation were considered. For the H3K36me3
mark, the number of overlapping elements was re-
corded. Those records were used to create a distribution
of overlaps for all lncRNAs, binned into 1-kb intervals.
The Kolmogorov-Smirnov (KS) test statistics was used
to compare continuous probability distributions of abun-
dance of each relevant genomic mark with those calcu-
lated for each of the 10 control random sets (p-values <
0.05 threshold).
To evaluate the tissue specificity of antisense lncRNAs
and protein-coding mRNAs expressed in renal cancer a
meta-analysis including Burge’s RNA-seq data from nine
human tissues [68] and strand-oriented Caltech RNA-
seq libraries from seven human cell lineages [69] was
performed. For the Burge RNA-seq data, we mapped the
transcripts to the hg19 reference genome (hg19 GRCh37)
using TopHat [99] and assembled the transcripts using
cufflinks [100]. RefSeq mRNA (October 2012, UCSC) plus
intronic antisense lncRNAs comprised in the 44 k array
were used as the reference transcripts. To determined tis-
sue specificity we used an approach similar to Marques
and Ponting [101]; thus we calculated the fraction of
expression in each tissue (F.E.T.) as being the FPKM
observed in a specific tissue divided by the sum of FPKMs
in all tissues. To address statistical significance, we
performed Fischer’s exact test comparing the rates of
F.E.T. ≥ 0.5 between the lncRNAs and the protein-coding
mRNAs (p < 0.001). The genomic coordinates of antisense
lncRNAs (or mRNAs) expressed in RCC were overlapped
with the coordinates of the Caltech RNA-seq data to
determine if the transcript was identified in each of the
strand-oriented RNA-seq libraries.
Conservation of expression pattern analyses were per-
formed by mapping the sequence coordinates of anti-
sense lncRNAs expressed in RCC to the coordinates of
transcripts expressed in humans and in 15 other
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vertebrate species, as compiled in the TransMap cross-
species syntenically mapped cDNA alignments [70], and
recording the hits in each species. To determine the stat-
istical significance of expression pattern conservation,
we compared the number of hits against the 15 species
obtained for the lncRNA sequences with the number of
hits against the 15 species obtained for 10 random sets
of sequences with identical length as those of the
lncRNAs. Fischer’s exact test (p < 0.05 threshold) was
used.
Conservation of expression pattern of intronic anti-
sense lncRNAs between RCC and intronic antisense
lncRNAs expressed in mouse [38] was identified by
transposing the mouse genomic coordinates to the hu-
man genome using the liftOver tool (http://genome.ucsc.
edu/cgi-bin/hgLiftOver), and the overlap between these
transcripts and the set of intronic antisense lncRNAs
expressed in RCC was determined using intersectBed
from the BEDtools package [97]. The same analysis was
done with the coordinates from a random set of 4303
sequences extracted from the subset of probes with no
evidence of expression in RCC among the entire set of
10,525 intronic antisense lncRNAs probed in the 44 k
array. Fisher test was used to determine statistical sig-
nificance (p < 0.05 threshold).
The analysis of DNA sequence conservation was per-
formed by cross-referencing the human genome coordi-
nates of antisense lncRNAs expressed in RCC with the
coordinates of PhastCons DNA conserved elements
from vertebrates, from placental mammalians and from
primates [61], and counting the number of overlaps. To
determine the statistical significance, the coordinates
from the 10 random sets described above were analyzed
in the same way against PhastCons dataset. Fischer’s
exact test (p < 0.05 threshold) was used.
RNAz tool [71] was used to predict structurally con-
served and thermodynamically stable RNA secondary
structures. Only predicted structures with P (Probability) >
0.5 were considered as containing conserved secondary
structures [71].
Additional files
Additional file 1: Table S1. Clinical and pathological data for the 18
clear cell RCC patients analyzed with the 4 k-element cDNA microarrays.
Additional file 2: Figure S1. Protein-coding gene expression signature
of ccRCC. Heat map of 217 differentially expressed protein-coding genes
(rows) identified in 11 ccRCC patients (columns) (FDR <5%; 1.5-fold
change). Patient ID numbers are indicated at the bottom. Blue indicates
lower expression, and red, higher expression in tumor (T) tissue in rela-
tion to adjacent nontumor (N) tissue.
Additional file 3: Table S2. List of 217 protein-coding genes differen-
tially expressed in ccRCC in the microarray analysis.
Additional file 4: Figure S2. Expression signature of intronic lncRNAs
correlated to patient survival in ccRCC. (A) A set of 26 intronic lncRNAs
(rows) identified as differentially expressed (FDR ≤5%; p <0.01) between
two ccRCC patient groups with distinct outcomes, namely alive and
disease-free or dead from cancer within a 5-year follow-up period after
surgery. Patient samples (columns) are ordered by their correlation rela-
tive to the mean expression profile of the group of patients that died
from cancer. The color code shows higher (red) or lower (blue) expres-
sion relative to the mean expression of that lncRNA in all patients. (B)
Clinical and pathological features: PS, Patient Status (white = alive
disease-free; black = cancer death); T, primary tumor classification (white
= 1a/1b; black = 2/3a/3b/3c); N, regional lymph node positive for metasta-
sis (white = no; black = yes); M, presence of metastasis at surgery (white
= no; black = yes); Necr, presence of necrosis (white = no; black = yes);
Sz, primary tumor size (white ≤ 7 cm; black > 7 cm); FG, Fuhrman’s nu-
clear grade (white = II; black = III/IV); Age, age at surgery (white ≤ 60-year-
old; black > 60-year-old); Gend, Gender (white = female; black = male).
(C) Correlation coefficient (r) of each sample in relation to the average ex-
pression profile of all samples from patients who died from the disease.
Patient samples were ordered according to this correlation.
Additional file 5: Table S3. List of 26 intronic lncRNAs significantly
correlated to RCC patient’s survival outcome identified through a cancer-
related death analysis of the microarray data.
Additional file 6: Table S4. ncHDAC5 lncRNA half-life measured in a
human renal cell line following transcriptional inhibition with actinomycin
D and ncHDAC5 lncRNA conserved secondary structure predictions calcu-
lated with the RNAz tool.
Additional file 7: Table S5. Clinical and pathological data of the 17
RCC patients analyzed with the 44 k-element oligoarrays.
Additional file 8: Table S6. List of 4303 intronic antisense lncRNAs
expressed in RCC. Information is provided for the evolutionary conservation
and for the cis-correlated analysis of expression in four tissues.
Additional file 9: Figure S3. All significantly enriched GO terms
identified for the set of protein-coding genes expressed in RCC and also
in other three human tissues (normal liver, prostate tumor and kidney
nontumor) and cis correlated (−0.5 > ρ >0.5; p < 0.05) with antisense
lncRNAs from the same loci. GO enriched terms are organized in Sub-
group I: biological regulation; Subgroup II: cellular process; Subgroup III:
developmental process. Subgroup IV: GO enriched terms for protein-
coding genes only showing positive cis correlation with the antisense
lncRNAs. Subgroup V: GO enriched terms for protein-coding genes only
showing negative cis correlation with the antisense lncRNAs. Color scale
indicates increasingly higher statistical significance of enriched GO terms:
Yellow, p =0.05; Dark orange, p <0.0001.
Additional file 10: Table S7. GO enriched terms from cis or trans
correlation analyses. (A) GO enriched terms for all protein-coding genes
with significant cis correlation with the lncRNA from the same locus. (B, C)
GO enriched terms for protein-coding genes with significant cis correl-
ation with the lncRNA from the same locus, for those only with (B) posi-
tive correlation or (C) negative correlation among lncRNAs and protein-
coding genes. (D) Average trans correlation value for the protein-coding
gene set expressed in RCC and other three tissues, belonging to that GO-
enriched term, and having significant trans correlation with a lncRNA. (E)
Correlation values for all lncRNAs with significant trans correlation with all
the protein-coding genes expressed in RCC plus other three tissues. (F)
Protein-coding genes expressed in RCC plus other three tissues, belong-
ing to that GO-enriched term in the trans correlation analysis.
Additional file 11: Figure S4. Heat map of trans-correlated expression
among the 20% most abundant antisense lncRNAs (n = 693) expressed in
RCC and other three tissues and the 5293 protein-coding mRNAs expressed
from different loci. A yellow entry indicates a Spearman correlation ρ ≥0.7; a
blue entry indicates a Spearman correlation ρ≤−0.7; a black entry indicates
all other correlation values. A total of 693 antisense lncRNAs and 5293
mRNAs expressed in the four tissues were considered in the trans-correlation
analysis.
Additional file 12: Figure S5. Tissue expression pattern of protein-
coding genes. (A) Heat map representing abundance of 5632 RCC-
expressed protein-coding genes (columns) across other nine human tis-
sues (rows) from public RNA-seq libraries [68]. Color intensity represents
fractional density expression of each lncRNA across all tissues (see
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Material and methods for details). (B) Heat map indicating presence (red)
or absence (white) of 5298 RCC-expressed protein-coding genes (columns)
across seven human cell lineages (rows) from public strand-oriented RNA-
Seq libraries [69]. Expression data was hierarchically clustered.
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